发明名称
摘要 <p>A method of treating a therapeutic condition comprising administering to a mammal in need of such treatment an effective amount of at least one compound of the formulas: or a pharmaceutically acceptable isomer, salt, solvate or co-crystal form thereof, wherein the substituents are as defined in the specification, wherein said therapeutic condition is a cardiovascular or circulatory disease or condition, an inflammatory disease or condition, a respiratory tract or disease or condition, cancer, acute renal failure, astrogliosis, a fibrotic disorder of the liver, kidney, lung or intestinal tract, Alzheimer's disease, diabetes, diabetic neuropathy, rheumatoid arthritis, neurodegenerative disease, neurotoxic disease, systemic lupus erythematosus, multiple sclerosis, osteoporosis, glaucoma, macular degeneration, psoriasis, radiation fibrosis, endothelial dysfunction, a wound or a spinal cord injury, or a symptom or result thereof. Combination therapy with other therapeutically effective agents is also disclosed.</p>
申请公布号 JP2007510750(A) 申请公布日期 2007.04.26
申请号 JP20060539810 申请日期 2004.11.09
申请人 发明人
分类号 A61K31/443;A61K31/343;A61K31/4436;A61K31/4439;A61K31/444;A61K31/4525;A61K31/4545;A61K31/4709;A61K31/506;A61P1/02;A61P1/04;A61P1/16;A61P3/10;A61P5/00;A61P7/02;A61P9/00;A61P9/04;A61P9/06;A61P9/08;A61P9/10;A61P9/12;A61P11/00;A61P11/06;A61P13/10;A61P13/12;A61P15/10;A61P17/00;A61P17/02;A61P17/06;A61P19/02;A61P19/10;A61P21/04;A61P25/00;A61P25/06;A61P25/14;A61P25/16;A61P25/28;A61P27/02;A61P27/06;A61P29/00;A61P35/00;A61P37/02;A61P43/00;C07D405/06;C07D405/14;C07D409/14;C07D413/14;C07D417/14;C07D521/00 主分类号 A61K31/443
代理机构 代理人
主权项
地址